Invitation to iCMLf Forum for physicians attending ASH 2017
Each year The Max Foundation and the International CML Foundation come together during the American Society of Hematology (ASH) Meeting to host a forum for physicians treating chronic myeloid leukemia (CML) in low resource settings. The aim is to provide resources, share programmatic updates and enable robust discussions between leading CML experts and those treating the disease in low- and middle-income countries. This year’s forum will have a new component of small group discussions to allow for a more intimate question & answer session.
If you are a physician attending ASH this year, please join us at the iCMLf Forum for Physicians from Emerging Economic Regions, carried out in partnership with The Max Foundation, on Friday 8th December at 12.30pm. The iCMLf Forum is a unique experience to discuss and share experiences from all around the world. We hope to hear yours!
The 2017 Forum features ‘Perspectives on the Management of CML’ covering the topics of Molecular Monitoring for CML and Treatment Free Remission. Speakers include Dr. Susan Branford (Australia), Dr. Katia Pagnano (Brazil) and Dr. Susanne Saussele (Germany). This year, there is an expanded format for physicians from low- and middle-income countries to “Meet the Expert” at the end of the meeting. In the small group sessions, physicians will be able to hear from and chat with CML experts around the management of TKIs.
The iCMLf Forum for Physicians from Emerging Regions will be held:
12.30pm – 3:30 pm on Friday 8th December at the Doubletree Downtown Atlanta, Georgia, USA
If you are traveling to ASH this year, please consider joining this meeting. Feel free to share this email and the attached invitation with your colleagues. Please click here to reserve your place or for any queries please email melissa@cml-foundation.org.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
The Max Foundation Announces Agreement with Lilly to Provide Access to Verzenio® (abemaciclib) for the Treatment of Advanced Breast Cancer in Kenya
Agreement to provide Verzenio® (abemaciclib) free of charge to patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) Lilly joins ongoing effort of Humanitarian Partnership for Access to Critical Treatment (Humanitarian PACT) to eliminate healthcare disparities for patients living with advanced breast cancer in low- and middle-income countries….
Welcoming Two New Board Members: Dr. Mika Matsuzaki and Dr. Susan M. Jerian
Please join us in welcoming Mika Matsuzaki, PhD, and Susan M. Jerian, MD to The Max Foundation Board of Directors.
The Max Foundation to Launch Treatment Access for Advanced Breast Cancer in Nine Countries Across Africa, Latin America, and South Asia in Q3 2023
The Max Foundation to launch its Max Access Solutions program for patients with HR+/HER2- advanced breast cancer in collaboration with leading oncologists in low- and middle-income countries (LMICs) and the ABC Global Alliance, the American Society for Clinical Pathology, Cepheid, and Novartis AG First patients to receive treatment in Bahamas, Benin, Bhutan, Haiti, Jamaica, Mozambique,….
The Max Foundation uses cookies to improve your experience on our site. Please read our Privacy Policy for more information.
